Amphastar receives fda approval for regadenoson

Rancho cucamonga, ca / accesswire / may 24, 2022 / amphastar pharmaceuticals, inc. (nasdaq:amph) announced that the u.s. food and drug administration ("fda") has approved the company's abbreviated new drug application ("anda") for regadenoson injection, 0.08 mg/ml, 5ml single dose pre-filled syringe. regadenoson is indicated for radionuclide myocardial perfusion imaging (mpi) in patients unable to undergo adequate exercise stress.
AMPH Ratings Summary
AMPH Quant Ranking